Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2014 (2014), Article ID 307872, 4 pages
http://dx.doi.org/10.1155/2014/307872
Case Report

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation

1Department of Neurology, MS Center Amsterdam, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
2Department of Neurology, ZGT, Almelo, The Netherlands
3Department of Radiology, ZGT, Almelo, The Netherlands
4Department of Radiology, Nuclear Medicine & PET Research, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands

Received 19 August 2014; Accepted 11 November 2014; Published 23 November 2014

Academic Editor: Filippo Martinelli Boneschi

Copyright © 2014 J. Killestein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Bloomgren, S. Richman, C. Hotermans et al., “Risk of natalizumab-associated progressive multifocal leukoencephalopathy,” The New England Journal of Medicine, vol. 366, no. 20, pp. 1870–1880, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Pilz, A. Harrer, P. Wipfler et al., “Tumefactive MS lesions under fingolimod: a case report and literature review,” Neurology, vol. 81, pp. 1914–1921, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Cohen, E. Maillart, A. Tourbah et al., “Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study,” JAMA Neurology, vol. 71, no. 4, pp. 436–441, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. V. G. Jokubaitis, V. Li, T. Kalincik et al., “Fingolimod after natalizumab and the risk of short-term relapse,” Neurology, vol. 82, no. 14, pp. 1204–1211, 2014. View at Publisher · View at Google Scholar
  5. T. Rispens, A. Vennegoor, G. J. Wolbink, C. H. Polman, and J. Killestein, “Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped,” Multiple Sclerosis Journal, vol. 18, no. 6, pp. 899–901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Stüve, C. M. Marra, K. R. Jerome et al., “Immune surveillance in multiple sclerosis patients treated with natalizumab,” Annals of Neurology, vol. 59, no. 5, pp. 743–747, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. Fine, A. Sorbello, C. Kortepeter, and L. Scarazzini, “Progressive multifocal leukoencephalopathy after natalizumab discontinuation,” Annals of Neurology, vol. 75, no. 1, pp. 108–115, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. M. P. Wattjes and J. Killestein, “Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true?” Annals of Neurology, vol. 75, no. 3, article 462, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. P. Wattjes, N. D. Richert, J. Killestein et al., “The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy,” Multiple Sclerosis Journal, vol. 19, no. 14, pp. 1826–1840, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. P. Wattjes and F. Barkhof, “Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI,” Current Opinion in Neurology, vol. 27, no. 3, pp. 260–270, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. R. Berger, A. J. Aksamit, D. B. Clifford et al., “PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section,” Neurology, vol. 80, no. 15, pp. 1430–1438, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Blinkenberg, F. Sellebjerg, A.-M. Leffers, C. G. Madsen, and P. S. Sørensen, “Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab,” Multiple Sclerosis Journal, vol. 19, no. 9, pp. 1226–1229, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. M. C. Kowarik, H. L. Pellkofer, S. Cepok et al., “Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS,” Neurology, vol. 76, no. 14, pp. 1214–1221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Rinaldi, D. Seppi, M. Calabrese, P. Perini, and P. Gallo, “Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings,” Multiple Sclerosis Journal, vol. 18, no. 11, pp. 1640–1643, 2012. View at Publisher · View at Google Scholar · View at Scopus